Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Alcohol Withdrawal and Dependence
NCT02903251Phase 3Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Oct 2016
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxytocin nasal spray in alcohol withdrawal syndrome (AWS) and alcohol dependence (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoints: Total oxazepam dosage at 3 days and Alcohol intake at 30 days. Started Oct 2016; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
alcohol withdrawal syndrome (AWS)alcohol dependence
Beyond the preview
Go deeper on NCT02903251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903251.